Novartis more upbeat on 2025 guidance after strong Q1 momentum

• click to rate

  Posted by Two Blokes Apr 29 - Filed in Stock - 1 view
  
  Novartis on Tuesday issued a more optimistic full-year earnings guidance, citing strong growth of drugs such as Kisqali, Kesimpta and Leqvio during the first quarter.